In the News

February 23, 2018
February 6, 2018

bioSyntagma Awarded National Science Foundation Phase II Small Business Innovation Research Grant

Phoenix, AZ— bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139. Upon completion of the Phase I SBIR, bioSyntagma successfully demonstrated feasibility of their technology, the LightStream FloCellTM, which visually maps […]

Read More


May 30, 2017

bioSyntagma Core Patent for Cancer Research Awarded by USPTO

Phoenix, AZ — bioSyntagma, LLC announced today that the United States Patent and Trademark Office fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE). This patent is the foundational technology for the company’s unique […]

Read More


About this project

Join us in making cancer research faster and more informative. bioSyntagma has developed a device that enables researchers and drug developers to get closer to making personalized medicine a reality by studying drug resistance in cancer patients.